IGC Pharma, Inc.IGC

IGC Pharma Inc. has filed its quarterly report for the three months ended 31 March 2026, and the document tells a story of ambition versus arithmetic. The company booked $317,000 of revenue, posted a net loss attributable to parent shareholders of $2.4 million, and consumed $1.2 million of operating cash, ending the period with just $207,000 in the till and $28,000 in short-term investments. The balance sheet still stands at $9.2 million in assets against $3.1 million in liabilities, but the gap between promise and purse is plain: stockholders’ equity is $6.1 million, which works out to about six bucks per share of tangible book value for a company whose headline therapy is still in mid-trial. (source: IGC 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1326205/000118518526001885/igc10q033126.htm)

IGC-AD1, the company’s lead candidate, is a Phase 2 treatment for agitation in Alzheimer’s disease and is being studied in the CALMA trial, a multicenter study the company expanded on 9 February 2026. The company also used its July 2026 investor presentation to tout a “potentially faster acting, larger effect size, and excellent safety profile,” alongside a side-by-side graph comparing IGC-AD1 against Brexpiprazole-complete with a black-box warning reminder for the comparator. The slide deck, however, omits the fact that the company does not yet sell any commercial product and therefore recognises no pharmaceutical revenue on its income statement. (source: IGC Pharma Investor Presentation, July 2026, https://www.sec.gov/Archives/edgar/data/1326205/000118518526002922/igcex99-1.htm; IGC 10-Q, 2026-05-15, https://www.sec.gov/Archives/edgar/data/1326205/000118518526001885/igc10q033126.htm)

On the capital-raising front, the company entered a $3 million credit facility with warrants priced at $0.03 per share in an 8-K filed on 13 July 2026, a structure that dilutes future shareholders at a price barely above the current bid. Research and development expense for the quarter was a tidy $1.3 million, while capitalised PP&E spend was a single $1,000 line item-so small it might have been a paperclip budget. Cash used in operating activities was $1.2 million, meaning the company burned through almost exactly what it spent on R&D. Diluted weighted average shares outstanding stand at 98.2 million, and EPS came in at minus $0.02. Inventory sits at $638,000 with no change in the quarter, a figure that sits awkwardly between the polished story of imminent blockbuster launch and the sober reality of a clinical-stage firm with no product on the market. (source: IGC 8-K, 2026-07-14, https://www.sec.gov/Archives/edgar/data/1326205/000118518526002922/igc8k071326.htm; IGC 10-Q, 2026-05-15, https://www.sec.gov/Archives/edgar/data/1326205/000118518526001885/igc10q033126.htm)

For readers who like to trace the gap between slideware and ledger, the July 2026 deck’s “ANNUAL REVENUE” table offers three upside scenarios at $3 billion, $5 billion, and $10 billion, complete with adoption assumptions-yet the filings show a company whose actual revenue is closer to the price of a mid-range cappuccino than the price of a breakthrough drug. The disconnect is not an opinion; it is a line-item fact visible in the 10-Q and echoed in the 8-Ks. (source: IGC Pharma Investor Presentation, July 2026, https://www.sec.gov/Archives/edgar/data/1326205/000118518526002922/igcex99-1.htm; IGC 10-Q, 2026-05-15, https://www.sec.gov/Archives/edgar/data/1326205/000118518526001885/igc10q033126.htm)

The company’s SEC filings remain the primary source for verifying every number cited here. The EDGAR index lists all submissions, and the companyfacts JSON provides XBRL-tagged data points from the latest filings, including the 10-Q for 31 March 2026 and the 8-Ks of 6 and 14 July 2026. (source: IGC SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1326205; IGC SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001326205.json)